KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Debt to Equity: 2010-2024

Historic Debt to Equity for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $1.37.

  • Emergent BioSolutions' Debt to Equity fell 12.55% to $1.14 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.14, marking a year-over-year decrease of 12.55%. This contributed to the annual value of $1.37 for FY2024, which is 99.91% up from last year.
  • Per Emergent BioSolutions' latest filing, its Debt to Equity stood at $1.37 for FY2024, which was up 99.91% from $0.69 recorded in FY2023.
  • Emergent BioSolutions' 5-year Debt to Equity high stood at $1.37 for FY2024, and its period low was $0.32 during FY2022.
  • Its 3-year average for Debt to Equity is $0.80, with a median of $0.69 in 2023.
  • Per our database at Business Quant, Emergent BioSolutions' Debt to Equity slumped by 35.65% in 2022 and then soared by 112.77% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Debt to Equity (Yearly) stood at $0.58 in 2020, then dropped by 13.35% to $0.50 in 2021, then tumbled by 35.65% to $0.32 in 2022, then spiked by 112.77% to $0.69 in 2023, then soared by 99.91% to $1.37 in 2024.